➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
AstraZeneca
Baxter
McKinsey

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SELENOMETHIONINE SE-75

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Selenomethionine Se-75

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00112892 ↗ Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors Completed Roswell Park Cancer Institute Phase 1 2004-08-01 RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of selenium when given together with irinotecan in treating patients with advanced solid tumors.
NCT00212186 ↗ Selenium Supplementation of Patients With Cirrhosis Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 1998-10-01 The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00212186 ↗ Selenium Supplementation of Patients With Cirrhosis Completed Vanderbilt University Medical Center N/A 1998-10-01 The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selenomethionine Se-75

Condition Name

Condition Name for Selenomethionine Se-75
Intervention Trials
Prostate Cancer 2
Stage IV Squamous Cell Carcinoma of the Larynx 1
Lung Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Selenomethionine Se-75
Intervention Trials
Prostatic Neoplasms 3
Carcinoma 2
Carcinoma, Non-Small-Cell Lung 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Selenomethionine Se-75

Trials by Country

Trials by Country for Selenomethionine Se-75
Location Trials
United States 11
New Zealand 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Selenomethionine Se-75
Location Trials
New York 7
Tennessee 2
Iowa 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Selenomethionine Se-75

Clinical Trial Phase

Clinical Trial Phase for Selenomethionine Se-75
Clinical Trial Phase Trials
Phase 2 4
Phase 1 5
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Selenomethionine Se-75
Clinical Trial Phase Trials
Completed 5
Terminated 3
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Selenomethionine Se-75

Sponsor Name

Sponsor Name for Selenomethionine Se-75
Sponsor Trials
Roswell Park Cancer Institute 6
National Cancer Institute (NCI) 4
Vanderbilt University Medical Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Selenomethionine Se-75
Sponsor Trials
Other 12
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKesson
Medtronic
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.